Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Jan
11
Today In Oncology
Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
Are Food Preservatives Linked to Increased Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo